EasyManua.ls Logo

Heska Element COAG - 9 Canine Fibrinogen Test; Fibrinogen Testing

Heska Element COAG
108 pages
Print Icon
To Next Page IconTo Next Page
To Next Page IconTo Next Page
To Previous Page IconTo Previous Page
To Previous Page IconTo Previous Page
Loading...
Chapter 9
9. Canine Fibrinogen Test
Figure 9.1:
Heska Element COAG
Ca-
nine Fibrinogen Test kit.
The Heska Element COAG
Canine Fib-
rinogen cartridge used with the Heska El-
ement COAG
Analyzer is designed to
measure the concentration of clottable fib-
rinogen in a canine (dog) plasma sample
using the Ellis–Stransky method.
Each Canine Fibrinogen cartridge con-
tains dual optical detection windows filled
with micro-channels.
The Canine Fibrinogen test cartridge mea-
sures the fibrinogen concentration from
100 µL
diluted plasma with nominal test
duration of approximately 10 minutes in-
cluding warm-up time.
9.1. Fibrinogen Testing
Fibrinogen (clotting factor I) is a coagulation protein produced by the liver and present in
plasma of all vertebrates [
18
,
19
]. It plays an important role in blood coagulation, cellular
interactions, inflammation and wound healing. Fibrinogen is also known as an acute
phase protein (APP) and has been widely used as a clinical indicator of acute or chronic
inflammation or tissue damage in mammals [18, 2022].
The canine normal range of plasma circulated fibrinogen is
1.2 g/L
to
3.0 g/L
. When
evaluating canine fibrinogen level, age has to be taken into consideration: younger dogs
show slight but statistically significant higher fibrinogen level [23].
In response to ongoing inflammation, fibrinogen plasma concentration changes within
24 to 48 hours [
24
]. The function and quantity of plasma fibrinogen can be altered by
both inherited and acquired disorders [
25
]. Fibrinogen is an essential component of
the hemostatic process and its level may be increased in response to inflammation, or
reduced due to consumption [
26
]. Low plasma fibrinogen concentration can indicate a
systemic activation of the clotting system, where consumption of clotting factors is faster
than synthesis, with increased risk of bleeding as a consequence.
67

Table of Contents

Related product manuals